



# ChemBank: A Small-Molecule Screening and Cheminformatics Resource Database

## Citation

Seiler, Kathleen Petri, Gregory A. George, Mary Pat Happ, Nicole E. Bodycombe, Hyman A. Carrinski, Stephanie Norton, Steve Brudz, et al. 2008. ChemBank: a small-molecule screening and cheminformatics resource database. *Nucleic Acids Research* 36(Supp. 1, Database issue): D351-D359.

## Published Version

doi:10.1093/nar/gkm843

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:4459224>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

# ChemBank: a small-molecule screening and cheminformatics resource database

Kathleen Petri Seiler, Gregory A. George, Mary Pat Happ, Nicole E. Bodycombe, Hyman A. Carrinski, Stephanie Norton, Steve Brudz, John P. Sullivan, Jeremy Muhlich, Martin Serrano, Paul Ferraiolo, Nicola J. Tolliday, Stuart L. Schreiber\* and Paul A. Clemons\*

Chemical Biology Program and Platform, Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA

Received August 17, 2007; Revised September 22, 2007; Accepted September 25, 2007

## ABSTRACT

**ChemBank** (<http://chembank.broad.harvard.edu/>) is a public, web-based informatics environment developed through a collaboration between the Chemical Biology Program and Platform at the Broad Institute of Harvard and MIT. This knowledge environment includes freely available data derived from small molecules and small-molecule screens and resources for studying these data. **ChemBank** is unique among small-molecule databases in its dedication to the storage of raw screening data, its rigorous definition of screening experiments in terms of statistical hypothesis testing, and its metadata-based organization of screening experiments into projects involving collections of related assays. **ChemBank** stores an increasingly varied set of measurements derived from cells and other biological assay systems treated with small molecules. Analysis tools are available and are continuously being developed that allow the relationships between small molecules, cell measurements, and cell states to be studied. Currently, **ChemBank** stores information on hundreds of thousands of small molecules and hundreds of biomedically relevant assays that have been performed at the Broad Institute by collaborators from the worldwide research community. The goal of **ChemBank** is to provide life scientists unfettered access to biomedically relevant data and tools heretofore available primarily in the private sector.

## INTRODUCTION

**ChemBank** v1.0 was initiated as a National Cancer Institute (NCI)-sponsored activity within the Initiative for Chemical Genetics (ICG), originally at Harvard's Institute of Chemistry and Cell Biology. The evolving interest of the NCI in sponsoring chemical-genetic research has been reported (1), as has the evolution of ICG as a public research effort dedicated to accelerating the discovery of cancer-relevant small-molecule probes (2). At present, **ChemBank** v2.0 (hereafter referred to as **ChemBank**) represents an evolving collaboration between the Chemical Biology Program and Chemical Biology Platform at the Broad Institute of Harvard and MIT, including interactions with academic synthetic chemists and biologists interested in high-throughput, small-molecule screening approaches.

**ChemBank** houses chemical structures and names, calculated molecular descriptors, human-curated biological information regarding small molecule activities, raw experimental results from high-throughput biological assays, and extensive metadata describing screening experiments. While there are many other publicly available small-molecule and drug databases [ChEBI (3), DrugBank (4), PubChem (5) and ZINC (6), among others], **ChemBank** is unique in three important ways: (i) its dedication to the storage of raw screening data; (ii) its rigorous definition of screening experiments in terms of statistical hypothesis testing; and (iii) its hierarchical metadata-based organization of related assays into screening projects. Moreover, the **ChemBank** website is more than a simple data repository; it contains tools for visualization and analysis of small-molecule results,

\*To whom correspondence should be addressed. Email: pclemons@broad.harvard.edu  
Correspondence may also be addressed to Stuart L. Schreiber. Email: stuart\_schreiber@harvard.edu

including raw and normalized high-throughput screening (HTS) data and chemical-genetic profiles. Data sets may be manipulated within *ChemBank* or downloaded for use with external analysis tools. *ChemBank* is a powerful knowledge repository and analysis environment for chemists and biologists alike.

## RESULTS

### *ChemBank* infrastructure


The *ChemBank* database consists of 95 tables segmented into seven logical groups representing compound information, molecular descriptors, assay results, assay metadata, biological findings, ontological associations and user information (Figure 1). Data from over 2500 high-throughput biological assays from 188 screening projects currently reside in *ChemBank*, with new assays loaded quarterly. *ChemBank* houses information on 1.7 million compound samples, representing more than 1.2 million unique small-molecule structures, with over 300 calculated molecular descriptor values for each molecule. Over 1000 proteins, 500 cell lines and 70 species are associated with the assays. *ChemBank* data are stored and searched using an Oracle 10g (Oracle Corporation; Redwood Shores, CA, USA) relational database extended with the DayCart Oracle cartridge (Daylight Chemical Information Systems; Aliso Viejo, CA, USA), which is used for molecule substructure and similarity searches.

### Data access and optional registration

Anyone with Internet access can use *ChemBank*, without registering with a username and password, using the

'Enter as a Guest' button. However, registration is highly encouraged of all users, as guest users are not permitted to export data from *ChemBank*. Registered users of *ChemBank* may download data directly from their search results using the '[export...]' hyperlinks on several *ChemBank* webpages. Downloadable result files are exported in tab-delimited text format for maximum flexibility of use in other applications. Simple Object Access Protocol (SOAP) web-service access is provided for much of the data in *ChemBank*. Service calls exist to list all projects and assays within *ChemBank*, as well as assay plates and well measurements. There are also molecule services allowing similarity and substructure searches of molecules within *ChemBank*. The Web-service Definition Language (WSDL) files for these services can be found on the *ChemBank* website (<http://chembank.broad.harvard.edu/webServices.htm>).

As a repository of primary data from HTS experiments, *ChemBank* employs a data-embargo strategy to protect newly generated data for a specified period, and accordingly, *ChemBank* comprises two separate websites containing overlapping datasets. Public *ChemBank* (<http://chembank.broad.harvard.edu/>) contains small-molecule assay data that are more than one year old as well as molecular descriptors and published bioactivity annotation for registered small molecules. Data-Sharing-Agreement (DSA)-*ChemBank* contains all of the data content of Public *ChemBank* as well as small-molecule assay data that are less than one year old. Use of the latter database is restricted to scientists who have deposited compounds or performed screening experiments at the Broad Institute of Harvard and MIT and who have signed



**Figure 1.** Conceptual summary of *ChemBank* schema. Logical illustration of *ChemBank* data model, in which 95 tables are organized into groups representing components of the chemical biology research enterprise. Each box represents several actual database tables, as indicated, and pseudocardinality relationships between boxes are meant to convey conceptual relationships, rather than the more complex cardinality relationships that relate the actual tables.

a DSA (<http://www.broad.harvard.edu/chembio/sci/screen/facil/DataSharingAgreement.pdf>). The DSA stipulates conditions of participation, such as shared authorship, intellectual property and expectations for sharing follow-up data. All scientists who have signed the agreement may browse the entire contents of DSA-*ChemBank* and renew their agreements annually for continued access to this resource. Registration for this version of *ChemBank* is required, and usernames and passwords are assigned by the *ChemBank* team upon receipt of the signed agreement. DSA-*ChemBank* users log in using their assigned username and password at a different URL (<http://chembank-dsa.broad.harvard.edu/>).

### ***ChemBank* queries, molecular properties and assay organization**

*ChemBank* has multiple search interfaces available to the user to enable both simple and complex queries. Users can search for small molecules using properties such as presence of a substructure (Figure 2a), calculated molecular descriptors (Figure 2b) or association with a curated biological activity (Figure 2c). Results from such searches lead the user to a 'Molecule Display' view, which shows basic information about the small molecule, including names, structure, chemical descriptors, biological activity and screening test instances (Figure 2, *background*).

Users may also search for specific screening assays by searching by assay or project names, by individual screeners or their home institution, by assay type or by the species (e.g. of a cell line) under investigation in a particular assay. Text searches within screening project descriptions are also supported. Assay search result webpages link to both assay and screening project information; a project is a grouping of assays under a single biological motivation. Details of an assay or screening project are displayed on their respective webpages, including user information and assay metadata (Figure 3).

Simple queries can be combined to generate complex, multi-criterion searches. *ChemBank* has an extensive multi-criterion search interface, which allows searches to be constructed interactively. This interface supports modification of prior search criteria or addition of new criteria, and can be used even after initial search results are returned. Additionally, data analysis on a single or combination of screens housed within *ChemBank* can be performed and visualized as detailed in the following section. More information on conducting *ChemBank* searches and webpages can be found in the Help section (<http://chembank.broad.harvard.edu/details.htm?tag=Help>).

### ***ChemBank* standard analysis model and visualizations**

*ChemBank* houses both raw and normalized experimental results from many HTS and small-molecule microarray (SMM) (7) projects. These datasets are the foundation for a data-analysis model specifically equipped to accumulate rich profiles of small-molecule performance across multiple, diverse biological assays. One of the primary requirements of this approach is a data-analysis strategy

for small-molecule performance that affords normalized values independent of both the screening technology platform and the specific biological question under investigation. *ChemBank* users are not restricted to this standard analysis paradigm; rather, each of the *ChemBank* data-visualization tools affords access to multiple data types along the analysis process, including raw data, background-subtracted data and replicate-handled data.

*ChemBank* seeks to provide cross-sectional analysis and multi-assay performance profiles (8–14). Therefore, we supplemented *ChemBank* raw screening data with normalized data using an error model with several salient features. First, it renders the results of multiple parallel assays formally comparable, regardless of the original signal amplitudes or units of measurement. Second, it introduces no assumptions about the strength of signal required to call screening positives. This condition rules out the use of arbitrary thresholds such as 2-fold induction or 50% inhibition (15,16). Third, it does not rely on global assumptions about the compound collection, particularly the assumption that most compounds will be inert in any given assay (17,18).

These three conditions suggested the use of only mock-treatment wells as a basis for well-to-well, plate-to-plate and experiment-to-experiment normalization. We reasoned that in any miniaturized assay of small-molecule performance, we can always define a mock-treatment condition that mirrors compound treatment in every way except for the presence of the compound. For example, in a typical HTS experiment, this condition is represented by the treatment of otherwise identical assay-well contents with the delivery vehicle, usually dimethylsulfoxide. We conceptualize our scoring method in terms of a formal hypothesis test comparing a compound-treatment with its associated mock-treatment distribution, and thus seek the most reliable estimates of the statistical parameters associated with this test. In an ideal world, one would simply make many measurements of a compound's performance in a particular assay system, and many measurements of the corresponding vehicle mock-treatment condition in that assay system. In such a case, our primary score for a compound would be similar to the  $Z'$  statistic for evaluating HTS methods during assay development (15,19). Since making a statistically meaningful number of measurements of each compound's performance is not practical, we estimate the parameters of the compound-treatment distribution from the parameters of the mock-treatment distribution. At present, *ChemBank* uses a constant-error assumption for plate-reader assays, and a variable error assumption for small-molecule microarrays (see subsequent paragraph).

To account for plate-to-plate variation in signal (15,16), the median raw value of mock-treatment signals on a given assay plate is subtracted from each mock-treatment value on the same plate (Figure 4a), providing a zero-centered distribution of mock-treatment measurements for each plate in one *experiment*. In *ChemBank*, a screening experiment is defined as a collection of distinct probe source plates (e.g. a multi-microtiter plate library) exposed to the same assay conditions at the same time.

**trichostatin A**

(2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo- (chemical), 2,4-heptahydroxy-4,6-dimethyl-7-oxo- (2E,4E,6R)- (chemical), 2,4-heptadienamide,7-[4-7-oxo- (2E,4E,6R)- (chemical), 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-di-4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamid hydroxy-4,6R-dimethyl-7-oxo-2E,4E-heptadienamide (chemical), antibiotic A3 primary-common, trichostatin A (common), TSA (common)

**Names:**

**SMILES:** C[C@H](/C=C(C(C)C=C(C(=O)NO)C(=O)c1ccc(cc1)N(C)C

**InChI:** 1/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)

**Pubchem Substances:** [11404391](#) [11120088](#) [11120576](#) [11121064](#) [11121779](#) [11122259](#) [111471370628](#) [11373667](#) [11376228](#)

**Molecular Weight:** 302.36818  
**Rotatable Bonds:** 6  
**HBond Acceptors:** 4  
**HBond Donors:** 2  
**LogP by GhoseCrippen:** 2.772  
[\[view all descriptors\]](#)

**search by substructure**

Draw the desired substructure with the JME molecular editor, or enter a SMILES or SMARTS string in the text box below, and then click the "add to search" button.

**search using descriptors**

Select one of the descriptors listed below, enter the value or range you would like to search, then click the "add to search" button. (The filters on the right side can be used to narrow the list of displayed descriptors. To filter by a full or partial descriptor name, enter the name in the "Name" field and then press the TAB key.)

Descriptors:

- Aromatic Rings
- Base Rings
- HBond Acceptors
- HBond Donors
- Negative Atoms
- Positive Atoms
- Rotatable Bonds

Filter:

Type: Count  
 Subtype: feature count  
 Source: <Any>  
 Name: (Press TAB to activate)

**search by function**

Select an Ontology below, then enter the term for which you wish to search and click the "add to search" button. (To choose from a list of all possible terms in an Ontology, select the Ontology below and then click on the looking glass to the right of the "Term" box.)

Ontology: Biological Process  
 Term: histone acetylation  
 Include child term matches

**Biochemical Interactions**

acts as an inhibitor of protein [Histone deacetylase](#)

**Therapeutic Uses**

immunosuppressive agent  
 anti-proliferative

**Biological Processes**

increases histone acetylation


**Sample Information**

Source	Library	Plate	Well	Virtual ID	Pubchem Substance	Autofluorescence <sup>1</sup>
Biomol	Bio1	1275	J09	Bio1_000207	<a href="#">11120088</a>	Not Tested
Biomol	Bio1	2169	J09	Bio1_000696	<a href="#">11120576</a>	Not Tested
Biomol	Bio1	2171	J09	Bio1_001185	<a href="#">11121064</a>	Not Tested
Biomol	Bio2	1362	L09	Bio2_000434	<a href="#">11121779</a>	Not Tested

**Figure 2.** ChemBank offers multiple routes to find chemical information. Search tools allowing structure drawing (28) for substructure or similarity searches (a), selection of calculated molecular descriptors (b) and selection of term-based bioactivity annotations (c), each provide avenues to find individual molecules or sets of molecules in ChemBank. The ChemBank 'Molecule Display' webpage (background) provides detailed information about each molecule, including structure, names, molecular descriptors, biological annotations, sample information and screening instances.

Next, the population of zero-centered measurements for all mock-treatment wells in the experiment are collected together, and values failing Chauvenet's criterion (20) for this overall distribution are discarded (Figure 4b), to protect against edge effects and other systematic artifacts known to present a technical problem for microtiter plate experiments (21,22). The remaining mock-treatment measurements are used to normalize each compound-treatment well measurement independently, first subtracting

the mean of remaining mock-treatment wells on the same plate to obtain background-subtracted values (Figure 4c), then dividing by the twice the standard deviation of mock-treatment wells in the same experiment to obtain dimensionless Z-scores (Figure 4d). (Note that using twice the standard deviation is a consequence of a constant-error assumption for microplate assays described in the preceding paragraph; a more general solution allows the error estimate for positive signals to



**Figure 3.** Relationship of ChemBank 'View Project' and 'View Assay' webpages. Screenshots of representative screening project and assay (inset) webpages. Emphasis (red boxes, arrow) has been added to highlight key information, including project description and motivation (a), individual assays within project (b), detailed description (shared by both webpages) of assay protocol (c) and individual screening plates within assay (d).

depend on signal strength, e.g., the scale factor used for small-molecule microarray experiments is very close to  $[1 + I_{\text{signal}}/I_{\text{mock}}]$ , as determined empirically using control arrays.) Thus, each compound well receives an algebraically signed *Z*-score corresponding to the number of standard deviations it fell above or below the mean of a well-defined mock-treatment distribution. Finally, as most screening experiments deposited in *ChemBank* were performed in two technical replicates (A and B), these replicates were combined to produce a *Composite Z-score* (Figure 4e) by scaling the vector  $[Z_A, Z_B]$  by the cosine correlation with a vector corresponding to 'perfect reproducibility' (i.e. equal *Z*-scores in both replicates). This overall normalization procedure is similar to that described in earlier work at the Broad Institute (9,12,23), and forms the basis for many of the *ChemBank* data visualizations available to users of the database (Figure 4f).


Currently, there are four available screening data visualizations in *ChemBank*. A simple heatmap visualization for assay plates corresponds to the microplate layout in a screening experiment (Figure 5a). For statistical analysis of results from multiple assay plates comprising a single HTS experiment, *ChemBank* offers both histogram (Figure 5b) and scatterplot (Figure 4e) views. Finally, multi-assay visualization is possible via the 'Feature Visualization' webpage (Figure 5c) which is

generated by implementation of the standard analysis model to provide a heatmap representing *ChemBank* 'Composite *Z*-score' values for a series of assays and compounds. These visualization tools can be used in conjunction with the structure similarity, substructure matching, and molecular descriptor filtering capabilities described previously to perform structure-activity relationship analyses (Figure 5d). Taken together, these search and visualization tools represent an implementation of chemical-genetic profiling and cheminformatic analysis capabilities within *ChemBank*.

#### Data curation and annotation

Data curation activities for *ChemBank* fall into two general categories: 1) annotation of information regarding small molecules, and 2) annotation of information regarding small-molecule assays. Annotations regarding small-molecule effects on biological systems are generated from the primary literature. Hyperlinks to other databases such as Entrez Gene (24), GO (25), MeSH (<http://www.nlm.nih.gov/mesh/meshhome.html>) and PubMed (5), are collected manually during curation activities.

Small molecules and clinically used drugs often have multiple names; some drugs have dozens of different brand and generic names. *ChemBank* names are curated from multiple sources including public databases, the United States Pharmacopeia (USP) Dictionary,



**Figure 4.** ChemBank standard data-analysis model for high-throughput small-molecule screens. All raw small-molecule assay results in ChemBank are further processed by comparing each measurement with the collection of mock-treatment well measurements performed in the same screening experiment. Median values from mock-treatment wells on the same plate are used in an initial zero-centering step (a), after which the distribution of mock-treatment measurements for the entire experiment is trimmed to eliminate systematic artifacts (b). Trimmed mock-treatment measurements are used to normalize assay performance by first subtracting the mean of trimmed mock-treatment measurements on the same plate to give 'background-subtracted values' (c), then dividing by twice the standard deviation of trimmed mock-treatment measurements for the entire experiment to give 'dimensionless Z-score values' (d). Replicate handling is performed by cosine correlation of the replicate pair (for screens done in duplicate) of 'dimensionless Z-score values' for each compound with a simple prior model of 'perfect reproducibility', to yield a 'Composite Z-score value' (e) that represents the final primary screening result. The ChemBank web interface provides access to raw and processed data types appropriate for each of its visualization tools (f).

the World Health Organization (WHO) International Non-proprietary Name database (<http://mednet.who.int/public/default.aspx?c=1f216b1a-c080-46a1-9a39-c33717387926>), and chemical vendor websites to provide an exhaustive list of names and synonyms for molecules.

For a subset of the bioactive small molecules in ChemBank, activity annotations from the biological literature have been added. Bioactivity annotations (see also Figure 2) are divided into four categories: (i) *Biochemical Interactions*, which indicate protein molecular targets or GO molecular functions (25) affected by the small molecule; (ii) *Therapeutic Indications*, which specify what diseases (i.e. MeSH terms) a small molecule is used to treat or manage; (iii) *Therapeutic Uses*, terms from an internally derived vocabulary that indicates what type of clinical or biological activity a small molecule possesses; and (iv) *Biological Processes*, which indicate GO biological processes affected by the small molecule. PubMed IDs (5) corresponding to these citations have been captured, but are not yet exposed to the user and GO terms (*Biochemical Interactions* and *Biological Processes*) describing the effect(s) of the small molecule (e.g. 'increases apoptosis') are displayed but do not currently connect directly to the GO website (<http://amigo.geneontology.org>).


Annotation surrounding biological assays is collected as field-based metadata using internal controlled vocabularies, and is used to describe screening projects,

experiments, and assay plates. Metadata associated with a screening project express the biological motivation and are displayed on the 'View Project' webpage; metadata associated with the details of a particular assay (instantiated as a screening 'experiment'; see above) are displayed on the 'View Assay' webpage (see also Figure 3).

For many of the most frequently screened small molecules in ChemBank, annotation of autofluorescence activity is available to reduce false positives by providing automated filtering in addition to detailed information about the optical properties of the compounds. Annotation includes a binary filter of autofluorescence, a plot of the range of wavelengths above a signal threshold, a plot of the shape of the spectra and a contour plot showing the autofluorescence over a range that includes wavelengths of common filter pairs. Additional details about autofluorescence detection and data-analysis methods are available on the ChemBank website (<http://chembank.broad.harvard.edu/details.htm?tag=Help#autoFluorMethodology>).

## DISCUSSION

ChemBank is a unique knowledge and analysis environment for small molecules and high-throughput small-molecule assays. It provides calculated molecular



**Figure 5.** Illustration of ChemBank visualizations and linking activities with chemical information. Screening data, including raw measurements, in ChemBank are addressable by exact plate and well position in assay plates (a), and statistical data representing outcomes (b) can be reviewed at the level of raw or normalized data. A multi-assay analysis capability takes advantage of the standard analysis procedure (Figure 4) to display the performance of such similar compounds in multiple assays to which each has been exposed (c). Each of these capabilities can be combined with structure and annotation-based search capabilities to provide cheminformatic analysis of molecules scoring as 'hits' in biological assays (d).

descriptors, experimental assay measurements, and literature-based annotation for small molecules, allowing integration of both new and established information in a single, public resource. Other public small-molecule databases exist, and the following examples are meant to be illustrative, not comprehensive. BindingDB (26) curates small-molecule binding affinities for protein targets from the literature. KEGG LIGAND (27) and its associated entry points seek to catalog and integrate chemical structures, biochemical reactions, and biological information into a single database. ZINC (6) is a database of three-dimensional compound structures intended for virtual screening applications. These products and the many other examples available serve to illustrate that each project has a different focus, and each is designed accordingly.

PubChem (5) is a public database, created by the NIH, that is most similar in aims and data content to ChemBank, but several important differences exist between ChemBank and PubChem (Table 1). Both databases house small-molecule structures and screening data, but ChemBank data are generated and annotated internally. PubChem is a deposition database, and relies on submission of data and structures from outside sources. Importantly, ChemBank houses raw screening data, including assay plate position information, and applies a standard data-analysis procedure to all datasets. PubChem does not require raw data or plate position information from submitters, and as such, interpretations of outcomes may be limited to those interpretations supplied by the submitting organization. ChemBank uses controlled vocabularies to capture metadata,



**Table 1.** Content and feature comparison between *ChemBank* v2.0 and PubChem

Database content/feature	<i>ChemBank</i> v2.0	PubChem
Chemical structure	>1.2 million unique	>10 million unique
Molecule names/synonyms	IUPAC and manually curated names/synonyms	IUPAC and depositor-supplied synonyms
Molecular descriptors	36 searchable plus >300 displayed calculated properties and descriptors per molecule	18 calculated chemical properties, atom types and stereochemistry flags per molecule
Literature annotations	Manually curated; connected to controlled vocabularies	Extensive linking to Entrez databases
Metadata describing screens	Extensive field-based metadata collected (some displayed); standardized terms connected to controlled vocabularies	Depositor-supplied comments; primarily free-text, no standard controlled vocabularies for assay components
Biological assay data	Raw data required with plate locations (except legacy <i>ChemBank</i> v1. × data sets); standard data-analysis model	~15% of assays display raw data; no standardized analysis performed beyond submitter interpretations
Screening assay analysis and visualization tools	Plate-map, histogram, scatterplot and multi-assay heat-map visualizations	Structure-activity relationship analyses; clustering visualizations
Public data submission	Required for Broad Institute screening center; limited external submissions	Required for Molecular Libraries Screening Centers; others may submit voluntarily

and especially provides for hierarchical organization of assays into projects; PubChem captures data and protocols in free text, and organizes data by submission, rather than grouping assays by common biological motivation. The primary strengths of PubChem are its very useful links to other Entrez databases and its capability to leverage the powerful Entrez search engine. However, although both databases house general small-molecule information and bioassay data, we believe that storage of plate locations and raw screening data, field-based metadata, and the standard experiment definition in *ChemBank* afford some distinct advantages over PubChem. In particular, we believe that *ChemBank* will be especially effective in revealing unrecognized small-molecule performance relationships because of its support of statistically rigorous cross-sectional analyses that harness the collective power of all experiments in the database (i.e. analyses of data derived from many different types of screens and small molecules).

By committing itself to storing raw screening data, defining screening experiments in a rigorous manner, and organizing screening experiments hierarchically using metadata, *ChemBank* provides a unique opportunity to the scientific community, even beyond computational scientists. *ChemBank* provides access to large volumes of data annotating chemical entities with measured outcomes, and the commitment to storage of raw data ensures that these measurements are available for data-mining activities. In this sense, *ChemBank* is an important social experiment in science, in that it permits an analysis of whether the interpretation of screening data by the investigators *performing* small-molecule screens indeed

reveal all the value in their performance. Alternatively, cross-sectional analysis of results deposited by multiple independent investigators may reveal outcomes not apparent to participants in any individual screening project. To that end, *ChemBank* allows customization of options for viewing chemical-genetic profiles for the resulting molecules using any associated assay data, and as such, allows users to exploit this assembled information to support discovery and experimentation in chemical biology research. The open, standardized data-sharing environment of *ChemBank* is geared toward rapid discovery of novel therapeutic candidates and a deep understanding of biological systems.

## ACKNOWLEDGEMENTS

The authors gratefully acknowledge the support of the National Cancer Institute's Initiative for Chemical Genetics (N01-CO-12400), the NIH Road Map's Exploratory Center for Cheminformatics Research (P20-HG003895), and the NIGMS Center for Chemical Methodologies and Library Development (P50-GM069721, including supplemental funds). We further acknowledge the Broad Institute's IT/Systems group for infrastructural support, and numerous contract workers who have helped to augment *ChemBank*'s contents: Natalia Balabi, Jose A. Fernandez, Cynthia A. Saraceni-Richards, Karen Rose, Laura Selfors, Nurgees Sulthan-Banu, Brian Weiner and Angela Zuniga-Meyer. Finally, we are indebted to the following investigators for early modeling efforts, helpful discussions and community participation during *ChemBank* development:

Elton Dean, David DeCaprio, Jay Duffner, Scott Eliasof, Joshua Forman, Annaliese Franz, Julie Gorenstein, Stephen Haggarty, Eugenia Harris, Angela Koehler, Andrew Lach, Justin Lamb, Julia Lamenza, Ralph Mazitschek, John McGrath, Olivia McPherson, Jared Shaw, Stanley Shaw, Lynn Verplank and Bridget Wagner. Funding to pay the Open Access publication charges for this article was provided by Initiative for Chemical Genetics (NO1-CO-12400).

**Conflict of interest statement.** We report that M.S. provided consultancy services, the subject(s) of which were unrelated to the *ChemBank* project, to Daylight Chemical Information Systems while participating in *ChemBank* development.

## REFERENCES

1. Strausberg,R.L. and Schreiber,S.L. (2003) From knowing to controlling: a path from genomics to drugs using small molecule probes. *Science*, **300**, 294–295.
2. Tolliday,N., Clemons,P.A., Ferraiolo,P., Koehler,A.N., Lewis,T.A., Li,X., Schreiber,S.L., Gerhard,D.S. and Eliasof,S. (2006) Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics. *Cancer Res.*, **66**, 8935–8942.
3. Brooksbank,C., Cameron,G. and Thornton,J. (2005) The European Bioinformatics Institute's data resources: towards systems biology. *Nucleic Acids Res.*, **33**, D46–D53.
4. Wishart,D.S., Knox,C., Guo,A.C., Shrivastava,S., Hassanali,M., Stothard,P., Chang,Z. and Woolsey,J. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.*, **34**, D668–D672.
5. Wheeler,D.L., Barrett,T., Benson,D.A., Bryant,S.H., Canese,K., Chetvernin,V., Church,D.M., DiCuccio,M., Edgar,R. *et al.* (2007) Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.*, **35**, D5–D12.
6. Irwin,J.J. and Shoichet,B.K. (2005) ZINC - a free database of commercially available compounds for virtual screening. *J. Chem. Inf. Model*, **45**, 177–182.
7. Duffner,J.L., Clemons,P.A. and Koehler,A.N. (2007) A pipeline for ligand discovery using small-molecule microarrays. *Curr. Opin. Chem. Biol.*, **11**, 74–82.
8. Fliri,A.F., Loging,W.T., Thadeio,P.F. and Volkmann,R.A. (2005) Biological spectra analysis: linking biological activity profiles to molecular structure. *Proc. Natl Acad. Sci. USA*, **102**, 261–266.
9. Franz,A.K., Dreyfuss,P.D. and Schreiber,S.L. (2007) Synthesis and cellular profiling of diverse organosilicon small molecules. *J. Am. Chem. Soc.*, **129**, 1020–1021.
10. Haggarty,S.J., Clemons,P.A. and Schreiber,S.L. (2003) Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. *J. Am. Chem. Soc.*, **125**, 10543–10545.
11. Kauvar,L.M., Higgins,D.L., Villar,H.O., Sportsman,J.R., Engqvist-Goldstein,A., Bukar,R., Bauer,K.E., Dille,H. and Rocke,D.M. (1995) Predicting ligand binding to proteins by affinity fingerprinting. *Chem. Biol.*, **2**, 107–118.
12. Kim,Y.K., Arai,M.A., Arai,T., Lamenza,J.O., Dean,E.F., III, Patterson,N., Clemons,P.A. and Schreiber,S.L. (2004) Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. *J. Am. Chem. Soc.*, **126**, 14740–14745.
13. Melnick,J.S., Janes,J., Kim,S., Chang,J.Y., Sipes,D.G., Gunderson,D., Jarnes,L., Matzen,J.T., Garcia,M.E. *et al.* (2006) An efficient rapid system for profiling the cellular activities of molecular libraries. *Proc. Natl Acad. Sci. USA*, **103**, 3153–3158.
14. Zaharevitz,D.W., Holbeck,S.L., Bowerman,C. and Svetlik,P.A. (2002) COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. *J. Mol. Graph Model*, **20**, 297–303.
15. Brideau,C., Gunter,B., Pikounis,B. and Liaw,A. (2003) Improved statistical methods for hit selection in high-throughput screening. *J. Biomol. Screen*, **8**, 634–647.
16. Gunter,B., Brideau,C., Pikounis,B. and Liaw,A. (2003) Statistical and graphical methods for quality control determination of high-throughput screening data. *J. Biomol. Screen*, **8**, 624–633.
17. Zhang,J.H., Chung,T.D. and Oldenburg,K.R. (2000) Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. *J. Comb. Chem.*, **2**, 258–265.
18. Zhang,J.H., Wu,X. and Sills,M.A. (2005) Probing the primary screening efficiency by multiple replicate testing: a quantitative analysis of hit confirmation and false screening results of a biochemical assay. *J. Biomol. Screen*, **10**, 695–704.
19. Zhang,J.H., Chung,T.D. and Oldenburg,K.R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen*, **4**, 67–73.
20. Bevington,P.R. and Robinson,D.K. (1991) *Data reduction and error analysis for the physical sciences, 2nd edn.* McGraw-Hill, Boston, MA.
21. Kelley,B.P., Lunn,M.R., Root,D.E., Flaherty,S.P., Martino,A.M. and Stockwell,B.R. (2004) A flexible data analysis tool for chemical genetic screens. *Chem. Biol.*, **11**, 1495–1503.
22. Root,D.E., Kelley,B.P. and Stockwell,B.R. (2003) Detecting spatial patterns in biological array experiments. *J. Biomol. Screen*, **8**, 393–398.
23. Kelly,K.A., Clemons,P.A., Yu,A.M. and Weissleder,R. (2006) High-throughput identification of phage-derived imaging agents. *Mol. Imaging*, **5**, 24–30.
24. Maglott,D., Ostell,J., Pruitt,K.D. and Tatusova,T. (2007) Entrez gene: gene-centered information at NCBI. *Nucleic Acids Res.*, **35**, D26–D31.
25. Gene Ontology,C. (2006) The Gene Ontology (GO) project in 2006. *Nucleic Acids Res.*, **34**, D322–D326.
26. Liu,T., Lin,Y., Wen,X., Jorissen,R.N. and Gilson,M.K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. *Nucleic Acids Res.*, **35**, D198–D201.
27. Kanehisa,M., Goto,S., Hattori,M., Aoki-Kinoshita,K.F., Itoh,M., Kawashima,S., Katayama,T., Araki,M. and Hirakawa,M. (2006) From genomics to chemical genomics: new developments in KEGG. *Nucleic Acids Res.*, **34**, D354–D357.
28. Ertl,P. and Jacob,O. (1997) WWW-based chemical information system. *J. Mol. Struct. Theochem*, **419**, 113.